Join
Live feed
·
PRReleasevia Quantisnow
Zymeworks Inc. logo

Zymeworks Announces Oral Presentation of Data from Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers at European Society for Medical Oncology (ESMO) Congress 2022 in Paris

ByQuantisnow·Wall Street's wire, on your screen.
ZYME· Zymeworks Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ZYME (Zymeworks Inc.) and more on Quantisnow.